• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

    2/9/24 4:05:33 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No.      7              )*

     

    HARROW HEALTH, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    415858109

     

    (CUSIP Number)

     

    James Silverman, One Boston Place, 26th Floor, Boston, MA 02108

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    12/31/23

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No. 41585810913GPage 2 of 6 Pages

     

    Opaleye Management, Inc.
     
    1.  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

    SOLE VOTING POWER

     

    0

      6.  

    SHARED VOTING POWER

     

    3,820,000

      7.  

    SOLE DISPOSITIVE POWER

     

    0

      8.  

    SHARED DISPOSITIVE POWER

     

    3,820,000

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,820,000

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    10.88%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

        * Based upon 35,117,746 shares of common stock outstanding on November 13, 2023 as reported by the Issuer in a 10-Q for the period ending on 9/30/2023 filed with the Securities and Exchange Commission. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

     
    CUSIP No. 41585810913GPage 3 of 6 Pages

     

    Item 1.

     

      (a)

    Name of Issuer: Harrow Health, Inc. (the “Company”).

         
      (b)

    Address of Issuer’s Principal Executive Offices: 102 Woodmont Blvd., Suite 610

    Nashville, Tennessee 37205

     

    Item 2.

     

      (a)

    Name of Person Filing This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the shares of common stock of the Company:

     

    Opaleye Fund

     

    Opaleye, L.P. (the “Opaleye Fund”), a private fund formed in the state of Delaware.

     

    Investment Manager

     

    Opaleye Management Inc. (the “Investment Manager”), with respect to the shares of common stock held by the Opaleye Fund, a private fund to which the Investment Manager serves as investment manager. The Investment Manager also serves as a portfolio manager for a separate managed account (the “Managed Account”) and may be deemed to indirectly beneficially own securities owned by the Managed Account. The Investment Manager disclaims beneficial ownership of the shares held by the Managed Account.

     

    Reporting Individual

     

    Mr. James Silverman (the “Reporting Individual”), with respect to the shares of common stock held by the Opaleye Fund. Mr. Silverman is the President of the Investment Manager.

         
      (b) Address of the Principal Office or, if none, residence One Boston Place, 26th Floor, Boston, MA 02108
         
      (c) Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
         
      (d) Title of Class of Securities Common Stock, $0.001 par value per share
         
      (e) CUSIP Number 415858109

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     
    CUSIP No. 41585810913GPage 4 of 6 Pages

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned: 3,820,000
           
      (b)   Percent of class: 10.88%
           
      (c)   Number of shares as to which the person has:
           
          (i) Sole power to vote or to direct the vote 0
             
          (ii) Shared power to vote or to direct the vote 3,820,000
             
          (iii) Sole power to dispose or to direct the disposition of .0
             
          (iv) Shared power to dispose or to direct the disposition of 3,820,000

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐ .

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

     
    CUSIP No. 41585810913GPage 5 of 6 Pages

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 41585810913GPage 6 of 6 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      02/09/2024
      Date
       
      /s/ James Silverman
      Signature
       
      James Silverman/Managing Member of Opaleye
       
      GP LLC, the General Partner of
       
      Opaleye, L.P.
      Name/Title

     

     

     

    Get the next $HROW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    9/24/2021$15.00Buy
    Aegis Capital
    7/2/2021$14.25Buy
    Ladenburg Thalmann
    More analyst ratings

    $HROW
    Leadership Updates

    Live Leadership Updates

    See more
    • Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

      1/7/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

      5/13/24 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth

      3/6/23 8:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harrow to Present at Two Investor Conferences in May

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA) Format: Fireside Chat, followed by 1x1 Investor Meetings Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025 Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN) Format: 1x1 and Small Group Investor Meetings Date/Time: Wednesday, May 28, 2025 Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum r

      5/14/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Financials

    Live finance-specific insights

    See more
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

      Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024 IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024 VEVYE® Access for All program expected to drive continued market share expansion in 2025 TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity H

      3/27/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Harrow with a new price target

      H.C. Wainwright initiated coverage of Harrow with a rating of Buy and set a new price target of $57.00

      2/6/25 7:06:49 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on Harrow with a new price target

      B. Riley Securities reiterated coverage of Harrow with a rating of Buy and set a new price target of $69.00 from $73.00 previously

      12/4/24 8:02:39 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Harrow with a new price target

      Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00

      4/11/24 7:51:28 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      12/5/24 7:08:52 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      10/8/24 6:41:41 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      2/13/24 5:25:53 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. sold $144,024 worth of shares (4,796 units at $30.03) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      6/5/25 4:05:47 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. sold $391,904 worth of shares (15,000 units at $26.13) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      5/14/25 4:56:15 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Large owner Opaleye Management Inc. sold $148,200 worth of shares (5,000 units at $29.64) (SEC Form 4)

      4/A - HARROW, INC. (0001360214) (Issuer)

      5/14/25 4:54:55 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/25/24 5:19:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/24/24 4:40:20 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/19/24 6:24:32 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    SEC Filings

    See more
    • SEC Form 10-Q filed by Harrow Inc.

      10-Q - HARROW, INC. (0001360214) (Filer)

      5/8/25 4:16:04 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HARROW, INC. (0001360214) (Filer)

      5/8/25 4:05:12 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Harrow Inc.

      DEFA14A - HARROW, INC. (0001360214) (Filer)

      4/25/25 8:01:18 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care